Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells

Journal of Controlled Release

Volumn 205, Issue , 2015, Pages 7-14

  Li, Shi Yong ^a,b   Sun, Rong ^b   Wang, Hong Xia ^b   Shen, Song ^b   Liu, Yang ^b   Du, Xiao Jiao ^b   Zhu, Yan Hua ^b   Jun, Wang ^b,c  

^a NANCHANG UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cancer stem cell; Combination therapy; Decitabine; Doxorubicin; Drug delivery

Indexed keywords

CELLS; CHEMOTHERAPY; CYTOLOGY; DISEASES; DRUG DELIVERY; DRUG DOSAGE; ENVIRONMENTAL REGULATIONS; NANOPARTICLES; STEM CELLS; TUMORS;

ALDEHYDE DEHYDROGENASE; CANCER STEM CELLS; CHEMOTHERAPEUTIC DRUGS; CHEMOTHERAPY RESPONSE; COMBINATION THERAPY; DECITABINE; DNA HYPERMETHYLATION; DOXORUBICIN;

DRUG THERAPY;

5 AZA 2' DEOXYCYTIDINE; ALDEHYDE DEHYDROGENASE; CASPASE 9; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; DOXORUBICIN; NANOPARTICLE; ANTINEOPLASTIC AGENT; AZACITIDINE; CASP9 PROTEIN, HUMAN; DECITABINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DRUG CARRIER; MACROGOL DERIVATIVE; POLYESTER; POLYLACTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG RETENTION; ENZYME ACTIVITY; IN VITRO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BREAST NEOPLASMS; CHEMISTRY; DNA METHYLATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MEDICINAL CHEMISTRY; METABOLISM; MULTICELLULAR SPHEROID; NANOMEDICINE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHARMACEUTICS; PROCEDURES; SCID MOUSE; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; BREAST NEOPLASMS; CASPASE 9; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, INBRED NOD; MICE, SCID; NANOMEDICINE; NANOPARTICLES; NEOPLASTIC STEM CELLS; POLYESTERS; POLYETHYLENE GLYCOLS; SPHEROIDS, CELLULAR; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926456748     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.11.011     Document Type: Article

References (44)

1. D.R. Youlden, S.M. Cramb, N.A. Dunn, J.M. Muller, C.M. Pyke, and P.D. Baade The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality Cancer Epidemiol. 36 2012 237 248
2. R.P. A'Hern, I.E. Smith, and S.R. Ebbs Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens Br. J. Cancer 67 1993 801 805
3. M.B. Gariboldi, R. Ravizza, R. Molteni, D. Osella, E. Gabano, and E. Monti Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line Cancer Lett. 258 2007 181 188
4. P. Van Phuc, P.L. Nhan, T.H. Nhung, N.T. Tam, N.M. Hoang, V.G. Tue, D.T. Thuy, and P.K. Ngoc Downregulation of CD44 reduces doxorubicin resistance of CD44 + CD24- breast cancer cells Onco Targets Ther. 4 2011 71 78
5. K. Chen, Y.H. Huang, and J.L. Chen Understanding and targeting cancer stem cells: therapeutic implications and challenges Acta Pharmacol. Sin. 34 2013 732 740
6. T.G. Natarajan, N. Ganesan, and K.T. Fitzgerald Cancer stem cells and markers: new model of tumorigenesis with therapeutic implications Cancer Biomark. 9 2010 65 99
7. D.Y. Shin, Y.S. Park, K. Yang, G.Y. Kim, W.J. Kim, M.H. Han, H.S. Kang, and Y.H. Choi Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation Int. J. Oncol. 41 2012 910 918
8. J. Lyons, E. Bayar, G. Fine, M. McCullar, R. Rolens, J. Rubinfeld, and C. Rosenfeld Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies Curr. Opin. Investig. Drugs 4 2003 1442 1450
9. K. Appleton, H.J. Mackay, I. Judson, J.A. Plumb, C. McCormick, G. Strathdee, C. Lee, S. Barrett, S. Reade, D. Jadayel, A. Tang, K. Bellenger, L. Mackay, A. Setanoians, A. Schatzlein, C. Twelves, S.B. Kaye, and R. Brown Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors J. Clin. Oncol. 25 2007 4603 4609
10. M. Karahoca, and R.L. Momparler Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy Clin. Epigenetics 5 2013 3 18
11. H.C. Tsai, H. Li, L. Van Neste, Y. Cai, C. Robert, F.V. Rassool, J.J. Shin, K.M. Harbom, R. Beaty, E. Pappou, J. Harris, R.W. Yen, N. Ahuja, M.V. Brock, V. Stearns, D. Feller-Kopman, L.B. Yarmus, Y.C. Lin, A.L. Welm, J.P. Issa, I. Minn, W. Matsui, Y.Y. Jang, S.J. Sharkis, S.B. Baylin, and C.A. Zahnow Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells Cancer Cell 21 2012 430 446
12. M. Lubbert, H. Bertz, B. Ruter, R. Marks, R. Claus, R. Wasch, and J. Finke Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients Bone Marrow Transplant. 44 2009 585 588
13. J.A. Beisler Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine J. Med. Chem. 21 1978 204 208
14. S.M. Taylor, and P.A. Jones Mechanism of action of eukaryotic DNA methyltransferase: use of 5-azacytosine-containing DNA J. Mol. Biol. 162 1982 679 692
15. H.M. Kantarjian, S. O'Brien, J. Cortes, F.J. Giles, S. Faderl, J.P. Issa, G. Garcia-Manero, M.B. Rios, J. Shan, M. Andreeff, M. Keating, and M. Talpaz Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia Cancer 98 2003 522 528
16. M.P. Melancon, R.J. Stafford, and C. Li Challenges to effective cancer nanotheranostics J. Control. Release 164 2012 177 182
17. P. Aksungur, M. Demirbilek, E.B. Denkbas, J. Vandervoort, A. Ludwig, and N. Unlu Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies J. Control. Release 151 2011 286 294
18. J.P. Salvage, S.F. Rose, G.J. Phillips, G.W. Hanlon, A.W. Lloyd, I.Y. Ma, S.P. Armes, N.C. Billingham, and A.L. Lewis Novel biocompatible phosphorylcholine-based self-assembled nanoparticles for drug delivery J. Control. Release 104 2005 259 270
19. X.Z. Yang, S. Dou, T.M. Sun, C.Q. Mao, H.X. Wang, and J. Wang Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy J. Control. Release 156 2011 203 211
20. C.Q. Mao, J.Z. Du, T.M. Sun, Y.D. Yao, P.Z. Zhang, E.W. Song, and J. Wang A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy Biomaterials 32 2011 3124 3133
21. J. Hrkach, D. Von Hoff, M. Mukkaram Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J.J. Song, Y.H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, P.W. Kantoff, N.H. Bander, C. Sweeney, O.C. Farokhzad, R. Langer, and S. Zale Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 4 2012 128 139
22. F. Ahmed, and D.E. Discher Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles J. Control. Release 96 2004 37 53
23. E. Blanco, E.A. Bey, Y. Dong, B.D. Weinberg, D.M. Sutton, D.A. Boothman, and J. Gao Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells J. Control. Release 122 2007 365 374
24. Y. Liu, Y.H. Zhu, C.Q. Mao, S. Dou, S. Shen, Z.B. Tan, and J. Wang Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles J. Control. Release 192 2014 114 121
25. V. Walia, and R.C. Elble Enrichment for breast cancer cells with stem/progenitor properties by differential adhesion Stem Cells Dev. 19 2010 1175 1182
26. M.J. Liao, C.C. Zhang, B. Zhou, D.B. Zimonjic, S.A. Mani, M. Kaba, A. Gifford, F. Reinhardt, N.C. Popescu, W. Guo, E.N. Eaton, H.F. Lodish, and R.A. Weinberg Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity Cancer Res. 67 2007 8131 8138
27. C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha, and G. Dontu ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 1 2007 555 567
28. S. Liu, C. Ginestier, E. Charafe-Jauffret, H. Foco, C.G. Kleer, S.D. Merajver, G. Dontu, and M.S. Wicha BRCA1 regulates human mammary stem/progenitor cell fate Proc. Natl. Acad. Sci. U. S. A. 105 2008 1680 1685
29. L. Kastl, I. Brown, and A.C. Schofield Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells Mol. Cell. Probes 24 2010 87 92
30. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
31. R. Singh, and J.W. Lillard Jr. Nanoparticle-based targeted drug delivery Exp. Mol. Pathol. 86 2009 215 223
32. V. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Deliv. Rev. 63 2011 131 135
33. H.C. Tsai, and S.B. Baylin Cancer epigenetics: linking basic biology to clinical medicine Cell Res. 21 2011 502 517
34. S.A. Wajed, P.W. Laird, and T.R. DeMeester DNA methylation: an alternative pathway to cancer Ann. Surg. 234 2001 10 20
35. K.D. Robertson DNA methylation, methyltransferases, and cancer Oncogene 20 2001 3139 3155
36. A. Ahluwalia, J.A. Hurteau, R.M. Bigsby, and K.P. Nephew DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells Gynecol. Oncol. 82 2001 299 304
37. J.E. Ohm, K.M. McGarvey, X. Yu, L. Cheng, K.E. Schuebel, L. Cope, H.P. Mohammad, W. Chen, V.C. Daniel, W. Yu, D.M. Berman, T. Jenuwein, K. Pruitt, S.J. Sharkis, D.N. Watkins, J.G. Herman, and S.B. Baylin A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing Nat. Genet. 39 2007 237 242
38. Y. Yamada, and A. Watanabe Epigenetic codes in stem cells and cancer stem cells Adv. Genet. 70 2010 177 199
39. M. Giachelia, F. D'Alo, E. Fabiani, N. Saulnier, A. Di Ruscio, F. Guidi, S. Hohaus, M.T. Voso, and G. Leone Gene expression profiling of myelodysplastic CD34 + hematopoietic stem cells treated in vitro with decitabine Leuk. Res. 35 2011 465 471
40. Z.T. Schafer, A.B. Parrish, K.M. Wright, S.S. Margolis, J.R. Marks, M. Deshmukh, and S. Kornbluth Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells Cancer Res. 66 2006 2210 2218
41. M. Ehrlichova, M. Koc, J. Truksa, Z. Naldova, R. Vaclavikova, and J. Kovarr Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells Anticancer Res. 25 2005 4215 4224
42. Y. Ding, and T.A. Nguyen PQ1, a quinoline derivative, induces apoptosis in T47D breast cancer cells through activation of caspase-8 and caspase-9 Apoptosis 18 2013 1071 1082
43. B.B. Wolf, M. Schuler, W. Li, B. Eggers-Sedlet, W. Lee, P. Tailor, P. Fitzgerald, G.B. Mills, and D.R. Green Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity J. Biol. Chem. 276 2001 34244 34251
44. M.S. Soengas, R.M. Alarcon, H. Yoshida, A.J. Giaccia, R. Hakem, T.W. Mak, and S.W. Lowe Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition Science 284 1999 156 159